Altimmune, Inc. (ALT) Form 8-K — Oct 27, 2026
Altimmune appointed Peter Greenleaf and Alex Howarth to its board effective November 2, 2026, expanding the board from nine to eleven directors.
Key figures
- Board size change
- nine to eleven directors
- Director annual cash retainer
- $40,000
- New director initial equity award
- stock options for 160,000 shares each
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.